New Therapies of Liver Diseases
In this Special Issue of the journal, advancements in the treatment of liver diseases are illustrated by international experts in the field. New treatment options for primary biliary cirrhosis and, hopefully, primary sclerosing cholangitis are discussed. Up-to-date pharmacological therapy for preven...
Saved in:
| Format: | Online |
|---|---|
| Language: | English |
| Published: |
MDPI - Multidisciplinary Digital Publishing Institute
2022
|
| Subjects: | |
| Online Access: | ONIX_20220506_9783036538594_122 |
| Tags: |
No Tags, Be the first to tag this record!
|
| _version_ | 1869523725766885376 |
|---|---|
| collection | Directory of Open Access Books |
| description | In this Special Issue of the journal, advancements in the treatment of liver diseases are illustrated by international experts in the field. New treatment options for primary biliary cirrhosis and, hopefully, primary sclerosing cholangitis are discussed. Up-to-date pharmacological therapy for preventing liver cirrhosis decompensation and treating acute-on-chronic liver failure is highlighted. Furthermore, new treatments for cholangiocarcinoma, based on biological and tissue markers, will be available in the near future, aiming to surpass the current unsatisfactory results of traditional therapies. Immunotherapy has been applied to hepatocellular carcinoma (HCC). The new first-line treatment, combining atezolizumab plus bevacizumab for HCC in the intermediate and advanced stages, will allow for an increase in patient survival in the near future. Liver transplantation (LT) remains the preferred treatment for many patients with end-stage liver diseases and HCC. The selection criteria for LT in patients with HCC moved from morphological to dynamic criteria, such as those derived from the assessment of tumor responses to locoregional and/or systemic treatments before transplantation. This allowed many patients who would have been excluded from a transplantation with the old selection criteria to access one. Finally, a very interesting issue regarding new indications for liver transplantation is illustrated. |
| format | Online |
| id | doab-20.500.12854ir-81056 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2022 |
| publishDateRange | 2022 |
| publishDateSort | 2022 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-810562024-03-31T13:09:04Z New Therapies of Liver Diseases Toniutto, Pierluigi tolvaptan cirrhotic ascites survival rate furosemide primary biliary cholangitis autoantibodies ursodeoxycholic acid treatment response second line therapy primary biliary cholangitis (PBC) primary sclerosing cholangitis (PSC) clinical trials ursodeoxycholic acid (UDCA) Farnesoid X Receptor (FXR) agonist Pan-Peroxisome Proliferator-Activated Receptor (PPAR) agonists liver cancer systemic treatment immunotherapy real-world unresectable hepatocellular carcinoma cirrhosis decompensation bleeding varices survival infection alcoholic hepatitis acute-on-chronic liver failure cholangiocarcinoma colorectal cancer metastases hepatocellular carcinoma liver transplantation Milan criteria alpha-fetoprotein solid organ transplantation liver injury immunosuppressant SARS-CoV-2 humoral response vaccination portal-systemic shunt ammonia vigilance HBV HDV antivirals functional cure pharmacology acute-on-chronic liver failure (ACLF) liver transplantation (LT) decompensated cirrhosis portal hypertension ascites non-selective beta-blockers TIPS rifaximin human albumin statins targeted therapy effective hypovolemia anti-mineralocorticoids loop diuretics vaptans n/a thema EDItEUR::M Medicine and Nursing::MB Medicine: general issues::MBN Public health and preventive medicine In this Special Issue of the journal, advancements in the treatment of liver diseases are illustrated by international experts in the field. New treatment options for primary biliary cirrhosis and, hopefully, primary sclerosing cholangitis are discussed. Up-to-date pharmacological therapy for preventing liver cirrhosis decompensation and treating acute-on-chronic liver failure is highlighted. Furthermore, new treatments for cholangiocarcinoma, based on biological and tissue markers, will be available in the near future, aiming to surpass the current unsatisfactory results of traditional therapies. Immunotherapy has been applied to hepatocellular carcinoma (HCC). The new first-line treatment, combining atezolizumab plus bevacizumab for HCC in the intermediate and advanced stages, will allow for an increase in patient survival in the near future. Liver transplantation (LT) remains the preferred treatment for many patients with end-stage liver diseases and HCC. The selection criteria for LT in patients with HCC moved from morphological to dynamic criteria, such as those derived from the assessment of tumor responses to locoregional and/or systemic treatments before transplantation. This allowed many patients who would have been excluded from a transplantation with the old selection criteria to access one. Finally, a very interesting issue regarding new indications for liver transplantation is illustrated. 2022-05-06T11:24:56Z 2022-05-06T11:24:56Z 2022 book ONIX_20220506_9783036538594_122 9783036538594 9783036538600 https://directory.doabooks.org/handle/20.500.12854/81056 eng image/jpeg Attribution 4.0 International https://mdpi.com/books/pdfview/book/5398 https://mdpi.com/books/pdfview/book/5398 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-0365-3860-0 10.3390/books978-3-0365-3860-0 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783036538594 9783036538600 236 Basel open access |
| spellingShingle | tolvaptan cirrhotic ascites survival rate furosemide primary biliary cholangitis autoantibodies ursodeoxycholic acid treatment response second line therapy primary biliary cholangitis (PBC) primary sclerosing cholangitis (PSC) clinical trials ursodeoxycholic acid (UDCA) Farnesoid X Receptor (FXR) agonist Pan-Peroxisome Proliferator-Activated Receptor (PPAR) agonists liver cancer systemic treatment immunotherapy real-world unresectable hepatocellular carcinoma cirrhosis decompensation bleeding varices survival infection alcoholic hepatitis acute-on-chronic liver failure cholangiocarcinoma colorectal cancer metastases hepatocellular carcinoma liver transplantation Milan criteria alpha-fetoprotein solid organ transplantation liver injury immunosuppressant SARS-CoV-2 humoral response vaccination portal-systemic shunt ammonia vigilance HBV HDV antivirals functional cure pharmacology acute-on-chronic liver failure (ACLF) liver transplantation (LT) decompensated cirrhosis portal hypertension ascites non-selective beta-blockers TIPS rifaximin human albumin statins targeted therapy effective hypovolemia anti-mineralocorticoids loop diuretics vaptans n/a thema EDItEUR::M Medicine and Nursing::MB Medicine: general issues::MBN Public health and preventive medicine New Therapies of Liver Diseases |
| title | New Therapies of Liver Diseases |
| title_full | New Therapies of Liver Diseases |
| title_fullStr | New Therapies of Liver Diseases |
| title_full_unstemmed | New Therapies of Liver Diseases |
| title_short | New Therapies of Liver Diseases |
| title_sort | new therapies of liver diseases |
| topic | tolvaptan cirrhotic ascites survival rate furosemide primary biliary cholangitis autoantibodies ursodeoxycholic acid treatment response second line therapy primary biliary cholangitis (PBC) primary sclerosing cholangitis (PSC) clinical trials ursodeoxycholic acid (UDCA) Farnesoid X Receptor (FXR) agonist Pan-Peroxisome Proliferator-Activated Receptor (PPAR) agonists liver cancer systemic treatment immunotherapy real-world unresectable hepatocellular carcinoma cirrhosis decompensation bleeding varices survival infection alcoholic hepatitis acute-on-chronic liver failure cholangiocarcinoma colorectal cancer metastases hepatocellular carcinoma liver transplantation Milan criteria alpha-fetoprotein solid organ transplantation liver injury immunosuppressant SARS-CoV-2 humoral response vaccination portal-systemic shunt ammonia vigilance HBV HDV antivirals functional cure pharmacology acute-on-chronic liver failure (ACLF) liver transplantation (LT) decompensated cirrhosis portal hypertension ascites non-selective beta-blockers TIPS rifaximin human albumin statins targeted therapy effective hypovolemia anti-mineralocorticoids loop diuretics vaptans n/a thema EDItEUR::M Medicine and Nursing::MB Medicine: general issues::MBN Public health and preventive medicine |
| topic_facet | tolvaptan cirrhotic ascites survival rate furosemide primary biliary cholangitis autoantibodies ursodeoxycholic acid treatment response second line therapy primary biliary cholangitis (PBC) primary sclerosing cholangitis (PSC) clinical trials ursodeoxycholic acid (UDCA) Farnesoid X Receptor (FXR) agonist Pan-Peroxisome Proliferator-Activated Receptor (PPAR) agonists liver cancer systemic treatment immunotherapy real-world unresectable hepatocellular carcinoma cirrhosis decompensation bleeding varices survival infection alcoholic hepatitis acute-on-chronic liver failure cholangiocarcinoma colorectal cancer metastases hepatocellular carcinoma liver transplantation Milan criteria alpha-fetoprotein solid organ transplantation liver injury immunosuppressant SARS-CoV-2 humoral response vaccination portal-systemic shunt ammonia vigilance HBV HDV antivirals functional cure pharmacology acute-on-chronic liver failure (ACLF) liver transplantation (LT) decompensated cirrhosis portal hypertension ascites non-selective beta-blockers TIPS rifaximin human albumin statins targeted therapy effective hypovolemia anti-mineralocorticoids loop diuretics vaptans n/a thema EDItEUR::M Medicine and Nursing::MB Medicine: general issues::MBN Public health and preventive medicine |
| url | ONIX_20220506_9783036538594_122 |